News
EQS-News: Relief gibt Kapitalerhöhung aus der letzten Tranche der Aktienzeichnungs-Fazilität mit GEM bekannt
EQS-News: Relief gibt Kapitalerhöhung aus der letzten Tranche der Aktienzeichnungs-Fazilität mit GEM bekannt
EQS-News: Relief Therapeutics Holdings AG: Relief Partner NeuroRx beantragt die Zulassung von RLF-100 (TM) (Aviptadil) als Notfallmedikament für Patienten mit kritischer COVID-19 und Atemversagen, die alle zugelassenen Therapien ausgeschöpft haben
EQS-News: Relief Therapeutics Holdings AG: Relief Partner NeuroRx beantragt die Zulassung von RLF-100 (TM) (Aviptadil) als Notfallmedikament für Patienten mit kritischer COVID-19 und Atemversagen, die alle zugelassenen Therapien ausgeschöpft haben
EQS-News: Relief partner NeuroRx submits request for Emergency Use Authorization for RLF-100(TM) (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy
EQS-News: Relief partner NeuroRx submits request for Emergency Use Authorization for RLF-100(TM) (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy
EQS-News: Relief und NeuroRx geben Partnerschaft zur weltweiten Kommerzialisierung von RLF-100 und zur Auswahl weiterer Vertriebspartner bekannt
EQS-News: Relief und NeuroRx geben Partnerschaft zur weltweiten Kommerzialisierung von RLF-100 und zur Auswahl weiterer Vertriebspartner bekannt
EQS-News: Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100(TM) and Selection of Commercial Partners
EQS-News: Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100(TM) and Selection of Commercial Partners
DGAP-News: Relief veröffentlicht Ergebnisse für das erste Halbjahr 2020
DGAP-News: Relief veröffentlicht Ergebnisse für das erste Halbjahr 2020
EQS-News: Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer
EQS-News: Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer
EQS-News: Relief ernennt Gilles Della Corte, M.D., zum Chief Medical Officer
EQS-News: Relief ernennt Gilles Della Corte, M.D., zum Chief Medical Officer
EQS-News: Relief gibt erfolgreiches Up-Listing von OTC Pink zu OTCQB sowie Kapitalerhöhung aus seiner Aktienzeichnungs-Fazilität mit GEM bekannt
EQS-News: Relief gibt erfolgreiches Up-Listing von OTC Pink zu OTCQB sowie Kapitalerhöhung aus seiner Aktienzeichnungs-Fazilität mit GEM bekannt
EQS-News: Relief Announces Successful Up-listing from OTC Pink to OTCQB and Capital Increase from its Share Subscription Facility with GEM
EQS-News: Relief Announces Successful Up-listing from OTC Pink to OTCQB and Capital Increase from its Share Subscription Facility with GEM
Relief Therapeutics has published its Annual Report
Relief Therapeutics has published its Annual Report
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement